Ardent Health Partners LLC (ARDT) reported solid topline growth in QQ2 2024, with revenue of $1.47092 billion, up 7.47% year over year and 2.21% quarter over quarter. The company posted a gross profit of $1.211529 billion and a robust gross margin of 82.36%, underscoring revenue quality despite a challenging operating expense environment. However, operating income remained negative at $(157.405) million, yielding an operating margin of −10.71% as elevated operating costs outpaced revenue gains. EBITDA stood at $136.655 million (EBITDA margin 9.29%), while net income reached $42.77 million with a 2.91% net margin and EPS of $0.30 for the quarter.
Cash flow dynamics remain constructive: net cash provided by operating activities was $117.994 million, and free cash flow totaled $79.067 million. The balance sheet shows a solid asset base and liquidity, with cash and cash equivalents of $334.538 million and current ratio of 1.652. On the flip side, leverage remains elevated: total debt of $2.24865 billion and net debt of $1.91411 billion drive a debt-to-capitalization of 0.752 and a debt-to-equity of 3.04, with an interest coverage of −8.67x given negative operating income. The company ended the period with total assets of $4.609 billion, total liabilities of $3.446 billion, and total stockholders’ equity of $739.899 million.
Overall, Ardent demonstrates revenue momentum and free cash flow generation in a high-leverage environment. The near-term investment thesis hinges on margin remediation and deleveraging, alongside disciplined capital deployment to sustain and grow cash generation. Absent explicit management guidance in the data, investors should monitor margin improvement initiatives, payer mix optimization, and debt refinancing plans as primary catalysts for a more favorable longer-term outlook.